nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—lung cancer	0.208	1	CbGaD
Ergotamine—ABCB1—Topotecan—lung cancer	0.0365	0.0791	CbGbCtD
Ergotamine—ABCB1—Gefitinib—lung cancer	0.0334	0.0723	CbGbCtD
Ergotamine—ABCB1—Vinorelbine—lung cancer	0.0257	0.0557	CbGbCtD
Ergotamine—CYP1A2—Erlotinib—lung cancer	0.0226	0.0489	CbGbCtD
Ergotamine—CYP3A4—Topotecan—lung cancer	0.0219	0.0474	CbGbCtD
Ergotamine—ABCB1—Crizotinib—lung cancer	0.0205	0.0443	CbGbCtD
Ergotamine—CYP3A4—Gefitinib—lung cancer	0.02	0.0433	CbGbCtD
Ergotamine—ABCB1—Gemcitabine—lung cancer	0.02	0.0433	CbGbCtD
Ergotamine—ABCB1—Erlotinib—lung cancer	0.0197	0.0428	CbGbCtD
Ergotamine—CYP3A4—Teniposide—lung cancer	0.0194	0.042	CbGbCtD
Ergotamine—ABCB1—Paclitaxel—lung cancer	0.0181	0.0392	CbGbCtD
Ergotamine—ABCB1—Irinotecan—lung cancer	0.0178	0.0386	CbGbCtD
Ergotamine—CYP1A2—Etoposide—lung cancer	0.0163	0.0354	CbGbCtD
Ergotamine—Localised oedema—Crizotinib—lung cancer	0.0163	0.0953	CcSEcCtD
Ergotamine—ABCB1—Vinblastine—lung cancer	0.0158	0.0343	CbGbCtD
Ergotamine—CYP3A4—Vinorelbine—lung cancer	0.0154	0.0334	CbGbCtD
Ergotamine—ABCB1—Cisplatin—lung cancer	0.0145	0.0315	CbGbCtD
Ergotamine—ABCB1—Etoposide—lung cancer	0.0143	0.0309	CbGbCtD
Ergotamine—ABCB1—Docetaxel—lung cancer	0.0131	0.0283	CbGbCtD
Ergotamine—CYP3A4—Crizotinib—lung cancer	0.0123	0.0266	CbGbCtD
Ergotamine—CYP3A4—Erlotinib—lung cancer	0.0118	0.0256	CbGbCtD
Ergotamine—CYP3A4—Paclitaxel—lung cancer	0.0108	0.0235	CbGbCtD
Ergotamine—CYP3A4—Irinotecan—lung cancer	0.0107	0.0231	CbGbCtD
Ergotamine—Ischaemia—Gefitinib—lung cancer	0.0102	0.0599	CcSEcCtD
Ergotamine—ABCB1—Doxorubicin—lung cancer	0.00974	0.0211	CbGbCtD
Ergotamine—CYP3A4—Vinblastine—lung cancer	0.0095	0.0206	CbGbCtD
Ergotamine—ABCB1—Methotrexate—lung cancer	0.00943	0.0204	CbGbCtD
Ergotamine—CYP3A4—Etoposide—lung cancer	0.00855	0.0185	CbGbCtD
Ergotamine—CYP3A4—Docetaxel—lung cancer	0.00783	0.017	CbGbCtD
Ergotamine—Gangrene—Gemcitabine—lung cancer	0.00709	0.0416	CcSEcCtD
Ergotamine—Ischaemia—Vinblastine—lung cancer	0.00635	0.0373	CcSEcCtD
Ergotamine—Ischaemia—Erlotinib—lung cancer	0.00611	0.0358	CcSEcCtD
Ergotamine—CYP3A4—Doxorubicin—lung cancer	0.00583	0.0126	CbGbCtD
Ergotamine—HTR2A—phrenic nerve—lung cancer	0.00523	0.368	CbGeAlD
Ergotamine—Localised oedema—Paclitaxel—lung cancer	0.00513	0.0301	CcSEcCtD
Ergotamine—Ischaemia—Irinotecan—lung cancer	0.00436	0.0256	CcSEcCtD
Ergotamine—Cyanosis—Teniposide—lung cancer	0.00429	0.0252	CcSEcCtD
Ergotamine—Paresthesia of limbs—Methotrexate—lung cancer	0.00413	0.0242	CcSEcCtD
Ergotamine—Peripheral coldness—Vinorelbine—lung cancer	0.00405	0.0237	CcSEcCtD
Ergotamine—Numbness—Vinblastine—lung cancer	0.0028	0.0164	CcSEcCtD
Ergotamine—Peripheral coldness—Paclitaxel—lung cancer	0.00272	0.016	CcSEcCtD
Ergotamine—Sensory loss—Vinblastine—lung cancer	0.00268	0.0157	CcSEcCtD
Ergotamine—Numbness—Vinorelbine—lung cancer	0.00232	0.0136	CcSEcCtD
Ergotamine—Sensory loss—Vinorelbine—lung cancer	0.00222	0.013	CcSEcCtD
Ergotamine—Bradycardia—Crizotinib—lung cancer	0.0021	0.0123	CcSEcCtD
Ergotamine—Hypoaesthesia—Crizotinib—lung cancer	0.00205	0.012	CcSEcCtD
Ergotamine—HTR2A—pulmonary artery—lung cancer	0.0019	0.134	CbGeAlD
Ergotamine—Cyanosis—Etoposide—lung cancer	0.00187	0.011	CcSEcCtD
Ergotamine—Numbness—Etoposide—lung cancer	0.00159	0.00935	CcSEcCtD
Ergotamine—Sensory loss—Etoposide—lung cancer	0.00153	0.00895	CcSEcCtD
Ergotamine—Sensory loss—Paclitaxel—lung cancer	0.0015	0.00878	CcSEcCtD
Ergotamine—Hypertension—Pemetrexed—lung cancer	0.00142	0.00831	CcSEcCtD
Ergotamine—Myalgia—Pemetrexed—lung cancer	0.0014	0.00819	CcSEcCtD
Ergotamine—Paraesthesia—Crizotinib—lung cancer	0.00132	0.00772	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Pemetrexed—lung cancer	0.00122	0.00715	CcSEcCtD
Ergotamine—Hypoaesthesia—Vinblastine—lung cancer	0.00116	0.0068	CcSEcCtD
Ergotamine—Hypertension—Teniposide—lung cancer	0.00115	0.00673	CcSEcCtD
Ergotamine—Pain—Pemetrexed—lung cancer	0.00114	0.00672	CcSEcCtD
Ergotamine—Pain—Gefitinib—lung cancer	0.00114	0.00667	CcSEcCtD
Ergotamine—Hypoaesthesia—Topotecan—lung cancer	0.00113	0.0066	CcSEcCtD
Ergotamine—Cyanosis—Methotrexate—lung cancer	0.00112	0.00656	CcSEcCtD
Ergotamine—Tachycardia—Teniposide—lung cancer	0.00106	0.00621	CcSEcCtD
Ergotamine—Asthenia—Crizotinib—lung cancer	0.00105	0.00617	CcSEcCtD
Ergotamine—Hypoaesthesia—Vinorelbine—lung cancer	0.000963	0.00565	CcSEcCtD
Ergotamine—Asthenia—Pemetrexed—lung cancer	0.00096	0.00563	CcSEcCtD
Ergotamine—Asthenia—Gefitinib—lung cancer	0.000954	0.0056	CcSEcCtD
Ergotamine—Pruritus—Pemetrexed—lung cancer	0.000947	0.00556	CcSEcCtD
Ergotamine—Pruritus—Gefitinib—lung cancer	0.000941	0.00552	CcSEcCtD
Ergotamine—Vomiting—Crizotinib—lung cancer	0.000931	0.00546	CcSEcCtD
Ergotamine—Vertigo—Vinblastine—lung cancer	0.000911	0.00534	CcSEcCtD
Ergotamine—Hypertension—Vinblastine—lung cancer	0.000875	0.00513	CcSEcCtD
Ergotamine—Nausea—Crizotinib—lung cancer	0.00087	0.0051	CcSEcCtD
Ergotamine—Vomiting—Pemetrexed—lung cancer	0.000851	0.00499	CcSEcCtD
Ergotamine—Vomiting—Gefitinib—lung cancer	0.000846	0.00496	CcSEcCtD
Ergotamine—Myalgia—Topotecan—lung cancer	0.000838	0.00492	CcSEcCtD
Ergotamine—Myalgia—Erlotinib—lung cancer	0.000829	0.00487	CcSEcCtD
Ergotamine—Bradycardia—Irinotecan—lung cancer	0.000812	0.00477	CcSEcCtD
Ergotamine—Nausea—Pemetrexed—lung cancer	0.000795	0.00466	CcSEcCtD
Ergotamine—Nausea—Gefitinib—lung cancer	0.00079	0.00463	CcSEcCtD
Ergotamine—Asthenia—Teniposide—lung cancer	0.000778	0.00456	CcSEcCtD
Ergotamine—Pruritus—Teniposide—lung cancer	0.000767	0.0045	CcSEcCtD
Ergotamine—Vertigo—Vinorelbine—lung cancer	0.000757	0.00444	CcSEcCtD
Ergotamine—Paraesthesia—Vinblastine—lung cancer	0.000743	0.00436	CcSEcCtD
Ergotamine—Bradycardia—Cisplatin—lung cancer	0.000738	0.00433	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Topotecan—lung cancer	0.000732	0.0043	CcSEcCtD
Ergotamine—Hypertension—Vinorelbine—lung cancer	0.000727	0.00427	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Erlotinib—lung cancer	0.000724	0.00425	CcSEcCtD
Ergotamine—Paraesthesia—Topotecan—lung cancer	0.000722	0.00423	CcSEcCtD
Ergotamine—ADRA1D—epithelium—lung cancer	0.000719	0.0506	CbGeAlD
Ergotamine—Myalgia—Vinorelbine—lung cancer	0.000717	0.00421	CcSEcCtD
Ergotamine—Pain—Vinblastine—lung cancer	0.000707	0.00415	CcSEcCtD
Ergotamine—Vomiting—Teniposide—lung cancer	0.000689	0.00404	CcSEcCtD
Ergotamine—Pain—Topotecan—lung cancer	0.000687	0.00403	CcSEcCtD
Ergotamine—Pain—Erlotinib—lung cancer	0.00068	0.00399	CcSEcCtD
Ergotamine—Tachycardia—Vinorelbine—lung cancer	0.000671	0.00394	CcSEcCtD
Ergotamine—Bradycardia—Paclitaxel—lung cancer	0.000663	0.00389	CcSEcCtD
Ergotamine—Hypoaesthesia—Etoposide—lung cancer	0.00066	0.00387	CcSEcCtD
Ergotamine—Hypoaesthesia—Paclitaxel—lung cancer	0.000648	0.0038	CcSEcCtD
Ergotamine—Nausea—Teniposide—lung cancer	0.000644	0.00378	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.000626	0.00367	CcSEcCtD
Ergotamine—Vertigo—Irinotecan—lung cancer	0.000624	0.00366	CcSEcCtD
Ergotamine—Paraesthesia—Vinorelbine—lung cancer	0.000617	0.00362	CcSEcCtD
Ergotamine—Hypertension—Irinotecan—lung cancer	0.0006	0.00352	CcSEcCtD
Ergotamine—Asthenia—Vinblastine—lung cancer	0.000593	0.00348	CcSEcCtD
Ergotamine—Pain—Vinorelbine—lung cancer	0.000588	0.00345	CcSEcCtD
Ergotamine—Hypertension—Gemcitabine—lung cancer	0.000584	0.00343	CcSEcCtD
Ergotamine—Asthenia—Topotecan—lung cancer	0.000577	0.00338	CcSEcCtD
Ergotamine—Myalgia—Gemcitabine—lung cancer	0.000576	0.00338	CcSEcCtD
Ergotamine—Asthenia—Erlotinib—lung cancer	0.00057	0.00335	CcSEcCtD
Ergotamine—Pruritus—Topotecan—lung cancer	0.000569	0.00334	CcSEcCtD
Ergotamine—Pruritus—Erlotinib—lung cancer	0.000563	0.0033	CcSEcCtD
Ergotamine—Hypoaesthesia—Docetaxel—lung cancer	0.000549	0.00322	CcSEcCtD
Ergotamine—Myalgia—Cisplatin—lung cancer	0.000537	0.00315	CcSEcCtD
Ergotamine—SLC6A2—respiratory system—lung cancer	0.000532	0.0374	CbGeAlD
Ergotamine—Vomiting—Vinblastine—lung cancer	0.000526	0.00309	CcSEcCtD
Ergotamine—Vertigo—Etoposide—lung cancer	0.000519	0.00305	CcSEcCtD
Ergotamine—Vomiting—Topotecan—lung cancer	0.000511	0.003	CcSEcCtD
Ergotamine—Paraesthesia—Irinotecan—lung cancer	0.000509	0.00299	CcSEcCtD
Ergotamine—Vertigo—Paclitaxel—lung cancer	0.000509	0.00299	CcSEcCtD
Ergotamine—Vomiting—Erlotinib—lung cancer	0.000506	0.00297	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000503	0.00295	CcSEcCtD
Ergotamine—Tachycardia—Cisplatin—lung cancer	0.000502	0.00295	CcSEcCtD
Ergotamine—Hypertension—Etoposide—lung cancer	0.000499	0.00293	CcSEcCtD
Ergotamine—Paraesthesia—Gemcitabine—lung cancer	0.000496	0.00291	CcSEcCtD
Ergotamine—Asthenia—Vinorelbine—lung cancer	0.000493	0.00289	CcSEcCtD
Ergotamine—Nausea—Vinblastine—lung cancer	0.000491	0.00288	CcSEcCtD
Ergotamine—Hypertension—Paclitaxel—lung cancer	0.000489	0.00287	CcSEcCtD
Ergotamine—Pruritus—Vinorelbine—lung cancer	0.000486	0.00285	CcSEcCtD
Ergotamine—Pain—Irinotecan—lung cancer	0.000485	0.00284	CcSEcCtD
Ergotamine—DRD2—respiratory system—lung cancer	0.000485	0.0341	CbGeAlD
Ergotamine—Myalgia—Paclitaxel—lung cancer	0.000482	0.00283	CcSEcCtD
Ergotamine—Nausea—Topotecan—lung cancer	0.000477	0.0028	CcSEcCtD
Ergotamine—Pain—Gemcitabine—lung cancer	0.000472	0.00277	CcSEcCtD
Ergotamine—Nausea—Erlotinib—lung cancer	0.000472	0.00277	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000469	0.00275	CcSEcCtD
Ergotamine—Paraesthesia—Cisplatin—lung cancer	0.000462	0.00271	CcSEcCtD
Ergotamine—Tachycardia—Etoposide—lung cancer	0.00046	0.0027	CcSEcCtD
Ergotamine—Tachycardia—Paclitaxel—lung cancer	0.000451	0.00265	CcSEcCtD
Ergotamine—Pain—Cisplatin—lung cancer	0.00044	0.00258	CcSEcCtD
Ergotamine—Vomiting—Vinorelbine—lung cancer	0.000437	0.00256	CcSEcCtD
Ergotamine—Paraesthesia—Etoposide—lung cancer	0.000423	0.00248	CcSEcCtD
Ergotamine—Dihydroergotamine—ABCB1—lung cancer	0.000423	0.415	CrCbGaD
Ergotamine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000421	0.00247	CcSEcCtD
Ergotamine—Paraesthesia—Paclitaxel—lung cancer	0.000415	0.00244	CcSEcCtD
Ergotamine—Hypertension—Docetaxel—lung cancer	0.000415	0.00243	CcSEcCtD
Ergotamine—ADRA1A—epithelium—lung cancer	0.000413	0.0291	CbGeAlD
Ergotamine—Myalgia—Docetaxel—lung cancer	0.000409	0.0024	CcSEcCtD
Ergotamine—CYP1A2—respiratory system—lung cancer	0.000409	0.0288	CbGeAlD
Ergotamine—Nausea—Vinorelbine—lung cancer	0.000408	0.0024	CcSEcCtD
Ergotamine—Asthenia—Irinotecan—lung cancer	0.000407	0.00239	CcSEcCtD
Ergotamine—Pain—Etoposide—lung cancer	0.000403	0.00237	CcSEcCtD
Ergotamine—Asthenia—Gemcitabine—lung cancer	0.000396	0.00232	CcSEcCtD
Ergotamine—Pain—Paclitaxel—lung cancer	0.000395	0.00232	CcSEcCtD
Ergotamine—Pruritus—Gemcitabine—lung cancer	0.000391	0.00229	CcSEcCtD
Ergotamine—Ergonovine—ABCB1—lung cancer	0.000387	0.379	CrCbGaD
Ergotamine—Tachycardia—Docetaxel—lung cancer	0.000382	0.00224	CcSEcCtD
Ergotamine—Asthenia—Cisplatin—lung cancer	0.000369	0.00217	CcSEcCtD
Ergotamine—Vomiting—Irinotecan—lung cancer	0.00036	0.00211	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000357	0.00209	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—lung cancer	0.000352	0.00206	CcSEcCtD
Ergotamine—Vomiting—Gemcitabine—lung cancer	0.000351	0.00206	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—lung cancer	0.00035	0.00206	CcSEcCtD
Ergotamine—Hypoaesthesia—Doxorubicin—lung cancer	0.000343	0.00201	CcSEcCtD
Ergotamine—Asthenia—Etoposide—lung cancer	0.000338	0.00198	CcSEcCtD
Ergotamine—Nausea—Irinotecan—lung cancer	0.000337	0.00198	CcSEcCtD
Ergotamine—Pain—Docetaxel—lung cancer	0.000335	0.00197	CcSEcCtD
Ergotamine—Pruritus—Etoposide—lung cancer	0.000334	0.00196	CcSEcCtD
Ergotamine—Asthenia—Paclitaxel—lung cancer	0.000332	0.00195	CcSEcCtD
Ergotamine—Nausea—Gemcitabine—lung cancer	0.000328	0.00192	CcSEcCtD
Ergotamine—Vomiting—Cisplatin—lung cancer	0.000327	0.00192	CcSEcCtD
Ergotamine—Pruritus—Paclitaxel—lung cancer	0.000327	0.00192	CcSEcCtD
Ergotamine—HTR2A—respiratory system—lung cancer	0.00032	0.0225	CbGeAlD
Ergotamine—HTR2B—lung—lung cancer	0.000318	0.0224	CbGeAlD
Ergotamine—Vertigo—Methotrexate—lung cancer	0.000311	0.00182	CcSEcCtD
Ergotamine—ADRA2A—bronchus—lung cancer	0.000309	0.0218	CbGeAlD
Ergotamine—Nausea—Cisplatin—lung cancer	0.000306	0.00179	CcSEcCtD
Ergotamine—Vomiting—Etoposide—lung cancer	0.0003	0.00176	CcSEcCtD
Ergotamine—Myalgia—Methotrexate—lung cancer	0.000295	0.00173	CcSEcCtD
Ergotamine—Vomiting—Paclitaxel—lung cancer	0.000294	0.00172	CcSEcCtD
Ergotamine—SLC6A2—lung—lung cancer	0.000282	0.0199	CbGeAlD
Ergotamine—Asthenia—Docetaxel—lung cancer	0.000281	0.00165	CcSEcCtD
Ergotamine—Nausea—Etoposide—lung cancer	0.00028	0.00164	CcSEcCtD
Ergotamine—ADRA2A—trachea—lung cancer	0.000278	0.0196	CbGeAlD
Ergotamine—Pruritus—Docetaxel—lung cancer	0.000277	0.00163	CcSEcCtD
Ergotamine—Nausea—Paclitaxel—lung cancer	0.000275	0.00161	CcSEcCtD
Ergotamine—Vertigo—Doxorubicin—lung cancer	0.000269	0.00158	CcSEcCtD
Ergotamine—HTR2A—epithelium—lung cancer	0.000267	0.0188	CbGeAlD
Ergotamine—ADRA2A—cardiac atrium—lung cancer	0.000261	0.0184	CbGeAlD
Ergotamine—Hypertension—Doxorubicin—lung cancer	0.000259	0.00152	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000257	0.00151	CcSEcCtD
Ergotamine—DRD2—lung—lung cancer	0.000257	0.0181	CbGeAlD
Ergotamine—Myalgia—Doxorubicin—lung cancer	0.000255	0.0015	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—lung cancer	0.000254	0.00149	CcSEcCtD
Ergotamine—Vomiting—Docetaxel—lung cancer	0.000249	0.00146	CcSEcCtD
Ergotamine—Pain—Methotrexate—lung cancer	0.000242	0.00142	CcSEcCtD
Ergotamine—Tachycardia—Doxorubicin—lung cancer	0.000239	0.0014	CcSEcCtD
Ergotamine—HTR2A—trachea—lung cancer	0.000236	0.0166	CbGeAlD
Ergotamine—Nausea—Docetaxel—lung cancer	0.000233	0.00137	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000223	0.00131	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—lung cancer	0.00022	0.00129	CcSEcCtD
Ergotamine—HTR2B—lymph node—lung cancer	0.000217	0.0153	CbGeAlD
Ergotamine—CYP1A2—lung—lung cancer	0.000217	0.0153	CbGeAlD
Ergotamine—Bromocriptine—ABCB1—lung cancer	0.00021	0.206	CrCbGaD
Ergotamine—ABCB1—respiratory system—lung cancer	0.000209	0.0147	CbGeAlD
Ergotamine—Pain—Doxorubicin—lung cancer	0.000209	0.00123	CcSEcCtD
Ergotamine—Asthenia—Methotrexate—lung cancer	0.000203	0.00119	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—lung cancer	0.0002	0.00117	CcSEcCtD
Ergotamine—ADRA2A—lung—lung cancer	0.0002	0.014	CbGeAlD
Ergotamine—SLC6A2—lymph node—lung cancer	0.000193	0.0136	CbGeAlD
Ergotamine—Vomiting—Methotrexate—lung cancer	0.00018	0.00105	CcSEcCtD
Ergotamine—Asthenia—Doxorubicin—lung cancer	0.000175	0.00103	CcSEcCtD
Ergotamine—ABCB1—epithelium—lung cancer	0.000175	0.0123	CbGeAlD
Ergotamine—Pruritus—Doxorubicin—lung cancer	0.000173	0.00102	CcSEcCtD
Ergotamine—HTR2A—lung—lung cancer	0.00017	0.0119	CbGeAlD
Ergotamine—Nausea—Methotrexate—lung cancer	0.000168	0.000984	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—lung cancer	0.000156	0.000912	CcSEcCtD
Ergotamine—ABCB1—trachea—lung cancer	0.000155	0.0109	CbGeAlD
Ergotamine—Nausea—Doxorubicin—lung cancer	0.000145	0.000852	CcSEcCtD
Ergotamine—ADRA2A—lymph node—lung cancer	0.000137	0.00961	CbGeAlD
Ergotamine—ABCB1—bone marrow—lung cancer	0.000123	0.00864	CbGeAlD
Ergotamine—ABCB1—lung—lung cancer	0.000111	0.00783	CbGeAlD
Ergotamine—ABCB1—lymph node—lung cancer	7.61e-05	0.00535	CbGeAlD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	5.65e-06	3.9e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—lung cancer	5.63e-06	3.88e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—lung cancer	5.62e-06	3.88e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—JUN—lung cancer	5.61e-06	3.87e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CG—lung cancer	5.59e-06	3.86e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—lung cancer	5.59e-06	3.86e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MTOR—lung cancer	5.58e-06	3.85e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	5.58e-06	3.85e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—lung cancer	5.56e-06	3.84e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—lung cancer	5.56e-06	3.84e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—lung cancer	5.53e-06	3.82e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—lung cancer	5.53e-06	3.81e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—lung cancer	5.48e-06	3.78e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—lung cancer	5.48e-06	3.78e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—lung cancer	5.46e-06	3.77e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—STK11—lung cancer	5.46e-06	3.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—lung cancer	5.44e-06	3.75e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	5.44e-06	3.75e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—lung cancer	5.44e-06	3.75e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—lung cancer	5.43e-06	3.75e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—lung cancer	5.43e-06	3.74e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—lung cancer	5.41e-06	3.73e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—lung cancer	5.4e-06	3.72e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—lung cancer	5.39e-06	3.72e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—lung cancer	5.38e-06	3.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	5.36e-06	3.7e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—lung cancer	5.36e-06	3.7e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	5.35e-06	3.69e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	5.33e-06	3.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MDM2—lung cancer	5.33e-06	3.68e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	5.33e-06	3.68e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—lung cancer	5.33e-06	3.67e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—POMC—lung cancer	5.33e-06	3.67e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—lung cancer	5.32e-06	3.67e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—lung cancer	5.32e-06	3.67e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RAF1—lung cancer	5.31e-06	3.66e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	5.3e-06	3.65e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—lung cancer	5.29e-06	3.65e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	5.29e-06	3.65e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—lung cancer	5.29e-06	3.65e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—lung cancer	5.28e-06	3.64e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—lung cancer	5.28e-06	3.64e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NRAS—lung cancer	5.27e-06	3.63e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—lung cancer	5.26e-06	3.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	5.25e-06	3.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—lung cancer	5.24e-06	3.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—lung cancer	5.23e-06	3.61e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—lung cancer	5.21e-06	3.6e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—lung cancer	5.21e-06	3.59e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CREBBP—lung cancer	5.19e-06	3.58e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—lung cancer	5.18e-06	3.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MTOR—lung cancer	5.18e-06	3.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	5.18e-06	3.58e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	5.18e-06	3.57e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—lung cancer	5.18e-06	3.57e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—JUN—lung cancer	5.17e-06	3.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—lung cancer	5.15e-06	3.55e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—lung cancer	5.13e-06	3.54e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—lung cancer	5.12e-06	3.54e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—lung cancer	5.12e-06	3.53e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—lung cancer	5.11e-06	3.52e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—lung cancer	5.11e-06	3.52e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—lung cancer	5.1e-06	3.52e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—lung cancer	5.1e-06	3.52e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—lung cancer	5.1e-06	3.52e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—JUN—lung cancer	5.09e-06	3.51e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NRAS—lung cancer	5.08e-06	3.51e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—lung cancer	5.07e-06	3.5e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NRAS—lung cancer	5.06e-06	3.49e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—lung cancer	5.05e-06	3.49e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	5.04e-06	3.48e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—lung cancer	5.03e-06	3.47e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—lung cancer	5.03e-06	3.47e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—lung cancer	5.02e-06	3.46e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—lung cancer	5.02e-06	3.46e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—lung cancer	5e-06	3.45e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—lung cancer	4.99e-06	3.45e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—lung cancer	4.99e-06	3.44e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—JUN—lung cancer	4.98e-06	3.44e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	4.98e-06	3.44e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—lung cancer	4.96e-06	3.42e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—lung cancer	4.95e-06	3.42e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	4.95e-06	3.41e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	4.93e-06	3.4e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—lung cancer	4.92e-06	3.4e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CD—lung cancer	4.92e-06	3.39e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAT—lung cancer	4.92e-06	3.39e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—lung cancer	4.91e-06	3.39e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	4.9e-06	3.38e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOA1—lung cancer	4.89e-06	3.38e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—lung cancer	4.88e-06	3.37e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—lung cancer	4.88e-06	3.37e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—lung cancer	4.87e-06	3.36e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—lung cancer	4.86e-06	3.35e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—lung cancer	4.85e-06	3.35e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—lung cancer	4.85e-06	3.35e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—lung cancer	4.84e-06	3.34e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NRAS—lung cancer	4.84e-06	3.34e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	4.83e-06	3.33e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—lung cancer	4.82e-06	3.33e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	4.81e-06	3.32e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—lung cancer	4.8e-06	3.31e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—lung cancer	4.8e-06	3.31e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—lung cancer	4.8e-06	3.31e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—lung cancer	4.78e-06	3.3e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—lung cancer	4.77e-06	3.29e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—lung cancer	4.77e-06	3.29e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—lung cancer	4.77e-06	3.29e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—lung cancer	4.76e-06	3.28e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—lung cancer	4.74e-06	3.27e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—lung cancer	4.74e-06	3.27e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—lung cancer	4.71e-06	3.25e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	4.7e-06	3.25e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—lung cancer	4.7e-06	3.24e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—lung cancer	4.7e-06	3.24e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.68e-06	3.23e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—lung cancer	4.67e-06	3.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—lung cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—lung cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—lung cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—lung cancer	4.63e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JUN—lung cancer	4.63e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	4.61e-06	3.18e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—lung cancer	4.61e-06	3.18e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—lung cancer	4.6e-06	3.17e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—lung cancer	4.59e-06	3.16e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—lung cancer	4.57e-06	3.15e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—lung cancer	4.53e-06	3.13e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—lung cancer	4.52e-06	3.12e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—lung cancer	4.51e-06	3.11e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—lung cancer	4.51e-06	3.11e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	4.49e-06	3.1e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—lung cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—lung cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—lung cancer	4.47e-06	3.08e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—lung cancer	4.47e-06	3.08e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NRAS—lung cancer	4.46e-06	3.08e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—lung cancer	4.46e-06	3.08e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—lung cancer	4.45e-06	3.07e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—lung cancer	4.41e-06	3.04e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—lung cancer	4.4e-06	3.04e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—lung cancer	4.4e-06	3.04e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1A1—lung cancer	4.4e-06	3.04e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NRAS—lung cancer	4.39e-06	3.03e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—lung cancer	4.39e-06	3.03e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—lung cancer	4.38e-06	3.02e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	4.37e-06	3.02e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—lung cancer	4.36e-06	3.01e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	4.35e-06	3e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—lung cancer	4.35e-06	3e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—lung cancer	4.31e-06	2.97e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—lung cancer	4.31e-06	2.97e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NRAS—lung cancer	4.3e-06	2.97e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CB—lung cancer	4.29e-06	2.96e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—lung cancer	4.28e-06	2.95e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—lung cancer	4.27e-06	2.95e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—lung cancer	4.27e-06	2.94e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—POMC—lung cancer	4.25e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—lung cancer	4.25e-06	2.93e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—lung cancer	4.21e-06	2.9e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—lung cancer	4.17e-06	2.88e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	4.17e-06	2.87e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—lung cancer	4.16e-06	2.87e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—lung cancer	4.15e-06	2.87e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CREBBP—lung cancer	4.14e-06	2.86e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	4.12e-06	2.84e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—lung cancer	4.09e-06	2.82e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—lung cancer	4.09e-06	2.82e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—lung cancer	4.07e-06	2.81e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—lung cancer	4.05e-06	2.79e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	4.05e-06	2.79e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—lung cancer	4.03e-06	2.78e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	4.02e-06	2.77e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—lung cancer	4.01e-06	2.76e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—lung cancer	4.01e-06	2.76e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—lung cancer	4e-06	2.76e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	4e-06	2.76e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NRAS—lung cancer	4e-06	2.76e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CD—lung cancer	3.93e-06	2.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—lung cancer	3.92e-06	2.7e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—lung cancer	3.89e-06	2.68e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—lung cancer	3.88e-06	2.67e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—lung cancer	3.87e-06	2.67e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—lung cancer	3.85e-06	2.66e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—lung cancer	3.84e-06	2.65e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	3.83e-06	2.64e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	3.83e-06	2.64e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—lung cancer	3.78e-06	2.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—lung cancer	3.78e-06	2.61e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOA1—lung cancer	3.78e-06	2.6e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—lung cancer	3.77e-06	2.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—lung cancer	3.72e-06	2.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—lung cancer	3.72e-06	2.57e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—lung cancer	3.7e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—lung cancer	3.7e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—lung cancer	3.7e-06	2.55e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—lung cancer	3.7e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—lung cancer	3.69e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—lung cancer	3.64e-06	2.51e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—lung cancer	3.56e-06	2.46e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—lung cancer	3.54e-06	2.44e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—lung cancer	3.54e-06	2.44e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—lung cancer	3.53e-06	2.44e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—lung cancer	3.53e-06	2.44e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	3.47e-06	2.4e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—lung cancer	3.45e-06	2.38e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.44e-06	2.37e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CB—lung cancer	3.42e-06	2.36e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—lung cancer	3.42e-06	2.36e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—lung cancer	3.4e-06	2.35e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	3.4e-06	2.35e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—lung cancer	3.39e-06	2.34e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—lung cancer	3.39e-06	2.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—lung cancer	3.36e-06	2.32e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—lung cancer	3.29e-06	2.27e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—lung cancer	3.28e-06	2.27e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—POMC—lung cancer	3.28e-06	2.26e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—lung cancer	3.27e-06	2.25e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—lung cancer	3.27e-06	2.25e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—lung cancer	3.21e-06	2.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CREBBP—lung cancer	3.2e-06	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	3.16e-06	2.18e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—lung cancer	3.15e-06	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—lung cancer	3.13e-06	2.16e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—lung cancer	3.13e-06	2.16e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—lung cancer	3.09e-06	2.13e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—lung cancer	3.08e-06	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—lung cancer	3.06e-06	2.11e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CD—lung cancer	3.03e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—lung cancer	3.01e-06	2.08e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—lung cancer	2.99e-06	2.06e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—lung cancer	2.96e-06	2.04e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—lung cancer	2.92e-06	2.02e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—lung cancer	2.88e-06	1.99e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—lung cancer	2.84e-06	1.96e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—lung cancer	2.82e-06	1.95e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—lung cancer	2.8e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—lung cancer	2.78e-06	1.92e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.64e-06	1.82e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—lung cancer	2.62e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—lung cancer	2.61e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.58e-06	1.78e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—lung cancer	2.28e-06	1.57e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—lung cancer	2.18e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—lung cancer	2.13e-06	1.47e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—lung cancer	2.09e-06	1.44e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—lung cancer	1.7e-06	1.18e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.61e-06	1.11e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—lung cancer	1.32e-06	9.08e-06	CbGpPWpGaD
